Details of Drug-Drug Interaction
| Drug General Information (ID: DDIAG7VMZO) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Triamcinolone (ophthalmic) | Drug Info | Methyltestosterone | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiinflammatory Agents | Androgens/Anabolic Steroids | |||||||
| Structure | |||||||||
| Mechanism of Triamcinolone (ophthalmic)-Methyltestosterone Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Potentiated the pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Triamcinolone (ophthalmic) | Methyltestosterone | |||||||
| Mechanism |
Steroidal effects Fluid retention |
Steroidal effects Fluid retention |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Enhanced pharmacological effects leading to increased adverse reactions. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. AndroGel (testosterone). Unimed Pharmaceuticals, Buffalo Grove, IL. | ||||||||||||||||||
| 2 | Product Information. Oxandrin (oxandrolone). Bio-Tech, Levittown, PA. | ||||||||||||||||||